{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:40:50Z","timestamp":1785796850863,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T00:00:00Z","timestamp":1337644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11010-012-1338-3","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T10:15:13Z","timestamp":1337595313000},"page":"17-25","source":"Crossref","is-referenced-by-count":38,"title":["Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E"],"prefix":"10.1007","volume":"368","author":[{"given":"Yuqing","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laijun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,22]]},"reference":[{"key":"1338_CR1","first-page":"85","volume":"25","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25:85\u2013109","journal-title":"J Natl Cancer Inst"},{"key":"1338_CR2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"1338_CR3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038\u20131042","journal-title":"N Engl J Med"},{"key":"1338_CR4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18:1321\u20131331","journal-title":"Leukemia"},{"key":"1338_CR5","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","volume":"111","author":"H Konig","year":"2008","unstructured":"Konig H, Holyoake TL, Bhatia R (2008) Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606. Blood 111:2329\u20132338","journal-title":"Blood"},{"key":"1338_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature03205","volume":"433","author":"JD Richter","year":"2005","unstructured":"Richter JD, Sonenberg N (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433:477\u2013480","journal-title":"Nature"},{"key":"1338_CR7","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1073\/pnas.93.3.1065","volume":"93","author":"D Rousseau","year":"1996","unstructured":"Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N (1996) Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci USA 93:1065\u20131070","journal-title":"Proc Natl Acad Sci USA"},{"key":"1338_CR8","first-page":"347","volume":"2","author":"A Benedetti De","year":"1994","unstructured":"De Benedetti A, Joshi B, Graff JR, Zimmer SG (1994) CHO cells transformed by the translation factor eIF4E display increased c-myc expression, but require overexpression of Max for tumorigenicity. Mol Cell Differ 2:347\u2013371","journal-title":"Mol Cell Differ"},{"key":"1338_CR9","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1158\/1535-7163.MCT-07-2357","volume":"7","author":"A Soni","year":"2008","unstructured":"Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F (2008) eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7:1782\u20131788","journal-title":"Mol Cancer Ther"},{"key":"1338_CR10","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1158\/0008-5472.CAN-08-3472","volume":"69","author":"JR Graff","year":"2009","unstructured":"Graff JR, Konicek BW, Lynch RL et al (2009) eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 69:3866\u20133873","journal-title":"Cancer Res"},{"key":"1338_CR11","first-page":"1343","volume":"20","author":"SG Zimmer","year":"2000","unstructured":"Zimmer SG, DeBenedetti A, Graff JR (2000) Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 20:1343\u20131351","journal-title":"Anticancer Res"},{"key":"1338_CR12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332\u2013337","journal-title":"Nature"},{"key":"1338_CR13","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1172\/JCI32044","volume":"117","author":"JR Graff","year":"2007","unstructured":"Graff JR, Konicek BW, Vincent TM et al (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117:2638\u20132648","journal-title":"J Clin Invest"},{"key":"1338_CR14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/0008-5472.CAN-07-5635","volume":"68","author":"JR Graff","year":"2008","unstructured":"Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68:631\u2013634","journal-title":"Cancer Res"},{"key":"1338_CR15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.bbrc.2010.06.015","volume":"397","author":"Y Ge","year":"2010","unstructured":"Ge Y, Zhou F, Chen H, Cui C, Liu D, Li Q, Yang Z, Wu G, Sun S, Gu J, Wei Y, Jiang J (2010) Sox2 is translationally activated by eukaryotic initiation factor 4E in human glioma-initiating cells. Biochem Biophys Res Commun 397:711\u2013717","journal-title":"Biochem Biophys Res Commun"},{"key":"1338_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2007.08.022","volume":"258","author":"SC Thumma","year":"2007","unstructured":"Thumma SC, Kratzke RA (2007) Translational control: a target for cancer therapy. Cancer Lett 258:1\u20138","journal-title":"Cancer Lett"},{"key":"1338_CR17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0162-3109(00)00256-3","volume":"49","author":"BY Kang","year":"2000","unstructured":"Kang BY, Chung SW, Kim SH, Ryu SY, Kim TS (2000) Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 49:355\u2013361","journal-title":"Immunopharmacology"},{"key":"1338_CR18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/emm.2005.18","volume":"37","author":"JM Hur","year":"2005","unstructured":"Hur JM, Shim JS, Jung HJ, Kwon HJ (2005) Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Exp Mol Med 37:133\u2013137","journal-title":"Exp Mol Med"},{"key":"1338_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-010-1440-8","volume":"68","author":"L Chen","year":"2010","unstructured":"Chen L, Zheng SZ, Sun ZG, Wang AY, Huang CH, Punchard NA, Huang SL, Gao X, Lu Y (2010) Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity. Cancer Chemother Pharmacol 68:17\u201327","journal-title":"Cancer Chemother Pharmacol"},{"key":"1338_CR20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/1940-6207.CAPR-10-0020","volume":"3","author":"W Chen","year":"2010","unstructured":"Chen W, Luo Y, Liu L, Zhou H, Xu B, Han X, Shen T, Liu Z, Lu Y, Huang S (2010) Cryptotanshinone inhibits cancer cell proliferation by suppressing mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev Res (Phila) 3:1015\u20131025","journal-title":"Cancer Prev Res (Phila)"},{"key":"1338_CR21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/sj.bjp.0707271","volume":"151","author":"MJ Don","year":"2007","unstructured":"Don MJ, Liao JF, Lin LY, Chiou WF (2007) Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway. Br J Pharmacol 151:638\u2013646","journal-title":"Br J Pharmacol"},{"key":"1338_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/0008-5472.CAN-08-2575","volume":"69","author":"DS Shin","year":"2009","unstructured":"Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 69:193\u2013202","journal-title":"Cancer Res"},{"key":"1338_CR23","first-page":"682","volume":"77","author":"T Tsuruo","year":"1986","unstructured":"Tsuruo T, Iida-Saito H, Kawabata H, Oh-hara T, Hamada H, Utakoji T (1986) Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res 77:682\u2013692","journal-title":"Jpn J Cancer Res"},{"key":"1338_CR24","doi-asserted-by":"crossref","first-page":"8992","DOI":"10.1128\/MCB.23.24.8992-9002.2003","volume":"23","author":"I Topisirovic","year":"2003","unstructured":"Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL (2003) Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 23:8992\u20139002","journal-title":"Mol Cell Biol"},{"key":"1338_CR25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11010-010-0669-1","volume":"349","author":"RB Cheng","year":"2011","unstructured":"Cheng RB, Ma RJ, Wang ZK, Yang SJ, Lin XZ, Rong H, Ma Y (2011) PTEN status is related to cell proliferation and self-renewal independent of CD133 phenotype in the glioma-initiating cells. Mol Cell Biochem 349:149\u2013157","journal-title":"Mol Cell Biochem"},{"key":"1338_CR26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1083\/jcb.200501019","volume":"169","author":"B Culjkovic","year":"2005","unstructured":"Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL (2005) eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3\u2032UTR. J Cell Biol 169:245\u2013256","journal-title":"J Cell Biol"},{"key":"1338_CR27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-2275(20)31588-1","volume":"42","author":"M Dean","year":"2001","unstructured":"Dean M, Hamon Y, Chimini G (2001) The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42:1007\u20131017","journal-title":"J Lipid Res"},{"key":"1338_CR28","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1248\/bpb.31.1258","volume":"31","author":"F Yan","year":"2008","unstructured":"Yan F, Jiang Y, Li YM, Zhen X, Cen J, Fang WR (2008) Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 isomers, tetrataisohydroquinolin derivatives. Biol Pharm Bull 31:1258\u20131264","journal-title":"Biol Pharm Bull"},{"key":"1338_CR29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153\u2013166","journal-title":"Nat Rev Cancer"},{"key":"1338_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/08977190500361812","volume":"24","author":"EA Musgrove","year":"2006","unstructured":"Musgrove EA (2006) Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24:13\u201319","journal-title":"Growth Factors"},{"key":"1338_CR31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","volume":"37","author":"JE Chipuk","year":"2010","unstructured":"Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR (2010) The BCL-2 family reunion. Mol Cell 37:299\u2013310","journal-title":"Mol Cell"},{"key":"1338_CR32","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","volume":"275","author":"J Yang","year":"1997","unstructured":"Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129\u20131132","journal-title":"Science"},{"key":"1338_CR33","doi-asserted-by":"crossref","first-page":"21312","DOI":"10.1074\/jbc.M312467200","volume":"279","author":"S Li","year":"2004","unstructured":"Li S, Perlman DM, Peterson MS, Burrichter D, Avdulov S, Polunovsky VA, Bitterman PB (2004) Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J Biol Chem 279:21312\u201321317","journal-title":"J Biol Chem"},{"key":"1338_CR34","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.onc.1209901","volume":"26","author":"S Prabhu","year":"2007","unstructured":"Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST (2007) A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 26:1188\u20131200","journal-title":"Oncogene"},{"key":"1338_CR35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2009-02-205153","volume":"114","author":"S Assouline","year":"2009","unstructured":"Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH Jr, Borden KL (2009) Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114:257\u2013260","journal-title":"Blood"},{"key":"1338_CR36","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3109\/10428194.2010.496506","volume":"51","author":"KL Borden","year":"2010","unstructured":"Borden KL, Culjkovic-Kraljacic B (2010) Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma 51:1805\u20131815","journal-title":"Leuk Lymphoma"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-012-1338-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11010-012-1338-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-012-1338-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T01:03:33Z","timestamp":1642295013000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11010-012-1338-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,22]]},"references-count":36,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1007\/s11010-012-1338-3","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,22]]}}}